Evidence map›Paper›PMID 26881967›Full record

ArticleEMBO molecular medicine2016

Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.

Nadiya M Teplyuk, Erik J Uhlmann, Galina Gabriely, Natalia Volfovsky, Yang Wang, Jian Teng, Priya Karmali, Eric Marcusson, Merlene Peter, Athul Mohan and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 135 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Nadiya M TeplyukDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Erik J UhlmannDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Galina GabrielyDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Natalia VolfovskySimons Foundation, New York, NY, USA.
Yang WangDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Jian TengDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Priya KarmaliRegulus Therapeutics Inc., San Diego, CA, USA.
Eric MarcussonRegulus Therapeutics Inc., San Diego, CA, USA.
Merlene PeterDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Athul MohanDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Yevgenya KraytsbergDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Ron CialicDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
E Antonio ChioccaDepartment of Neurosurgery, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Jakub GodlewskiDepartment of Neurosurgery, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
Bakhos TannousDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Anna M KrichevskyDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA akrichevsky@rics.bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USMassachusetts General Hospital · USRegulus Therapeutics (United States) · USSimons Foundation · US

Funding

MicroRNA128 Regulation of Polycomb Repressor Complexes1 and 2 in GlioblastomaR01CA176203 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GODLEWSKI, JAKUB · 2014 to 2018
$1.8M
Validation of microRNA Targets in GliomaR01CA138734 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KRICHEVSKY, ANNA M. · 2010 to 2014
$1.7M
NCI NIH HHS R01 CA138734NCI NIH HHS R01CA138734NCI NIH HHS R01 CA176203
6 · The paper itself

Abstract

MicroRNA-10b (miR-10b) is a unique oncogenic miRNA that is highly expressed in all GBM subtypes, while absent in normal neuroglial cells of the brain. miR-10b inhibition strongly impairs proliferation and survival of cultured glioma cells, including glioma-initiating stem-like cells (GSC). Although several miR-10b targets have been identified previously, the common mechanism conferring the miR-10b-sustained viability of GSC is unknown. Here, we demonstrate that in heterogeneous GSC, miR-10b regulates cell cycle and alternative splicing, often through the non-canonical targeting via 5'UTRs of its target genes, including MBNL1-3, SART3, and RSRC1. We have further assessed the inhibition of miR-10b in intracranial human GSC-derived xenograft and murine GL261 allograft models in athymic and immunocompetent mice. Three delivery routes for the miR-10b antisense oligonucleotide inhibitors (ASO), direct intratumoral injections, continuous osmotic delivery, and systemic intravenous injections, have been explored. In all cases, the treatment with miR-10b ASO led to targets' derepression, and attenuated growth and progression of established intracranial GBM. No significant systemic toxicity was observed upon ASO administration by local or systemic routes. Our results indicate that miR-10b is a promising candidate for the development of targeted therapies against all GBM subtypes.

Indexed as

AllograftsAnimalsAntineoplastic AgentsDisease Models, AnimalGlioblastomaHeterograftsHumansMiceMicroRNAsOligonucleotides, AntisenseTreatment OutcomeAntineoplastic AgentsMicroRNAsMIRN10 microRNA, mouseOligonucleotides, Antisensealternative splicingbrain tumormicroRNAoligonucleotide therapeuticsstem cells

Identifiers

PMID26881967
PMCPMC4772951
OpenAlexW2262087088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.